7a-Methyl-estra-4-en-3,17-dione (Mentabolan, MENT, 7-MENT)
AKA 7a-methyl-19-norandrostenedione, Mentabolan, MENT dione, Trestione.
A brand new prohormone from Prohormone Forum/IBE. It was synthesized and tested for anabolic and androgenic activity in 1963.
This compound is a "19-nor", or nandrolone derivative, and differs from nandrolone in that this hormone has a 17-ketone, where nandrolone has a 17b-hydroxy function, and also has the addition of a 7a-methyl group. In the same way as "Boladrol" is a 7a-methylated dione version of methyl testosterone, this compound is a 7a-methylated dione version of nandrolone.
Effects should be similar to the injectable trestolone acetate. It's a strongly anabolic, moderately androgenic compound which should elicit significant strength gains and increased muscle mass at an appropriate dosage.
Side-effects may include those common to anabolic androgenic steroids, including but not limited to: blood pressure increases, HPTA disruption, adverse shifts in lipoprotein subfractions (increased HDL, lowered LDL cholesterol), acne, hair growth or loss. This product should not be used by women or teens. There's evidence of aromatization to some degree, so the gyno-prone may wish to either avoid this compound or co-administer an aromatase inhibitor (AI) or selective estrogen receptor modulator (SERM) while using it.
One side-effect that many might fear from this compound is the loss of libido and/or erectile dysfunction often seen with 19-nor derivatives. Tests conducted with the target hormone trestolone (MENT) have found that it had a positive mood, libido, and erection-stimulating effect similar to that of testosterone, though this may not necessarily hold true with the supraphysiological doses used by bodybuilders.
This is a "dione" prohormone. In the body, the ketone at C17 will be hydrolysed by 17b-hydroxysteroid dehydrogenase type 1 (17b-HSD1) into the active compound trestolone (MENT). Trestolone itself has been shown to be roughly 6 times as anabolic as methyl test by oral administration, and around 2.5 times as androgenic.
Trestolone shows no affinity for SHBG, so all of the converted compound in circulation should be bioavailable. For the same reason, it's likely to have a short terminal half-life so frequent dosing is suggested.
Testosterone and similar delta-4 steroids are typically converted to stronger compounds like DHT and DHT derivatives by the enzyme 5-alpha reductase (5AR). 19-nor compounds are an exception to this rule, with 5a-reduced nandrolone (or 19-nor DHT) being a far less potent androgen than nandrolone itself. The 7a-methylation of trestolone hinders the reduction of this double bond, so delta 5(10) isomers are a major excreted metabolite. This means the 7a-methyl group not only makes the compound stronger by increasing androgen receptor affinity, but also reduces the ability of the body's enzymes to break it down into weaker metabolites.
The addition of the 7a-methyl group has a flattening effect on the molecule which improves androgen receptor binding. MENT is a strong compound for several reasons, but the primary reason for its strength is the increased androgen receptor affinity caused by the conformational changes of the 7a-methyl group.
